{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:46Z","timestamp":1793608186870,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2039\/20"],"award-info":[{"award-number":["2039\/20"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001738","name":"Israel Ministry of Innovation Science & Technology","doi-asserted-by":"publisher","award":["3-17632"],"award-info":[{"award-number":["3-17632"]}],"id":[{"id":"10.13039\/501100001738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KEREM19KO"],"award-info":[{"award-number":["KEREM19KO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WILSCH20K0"],"award-info":[{"award-number":["WILSCH20K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:24:56Z","timestamp":1767788696000},"page":"718-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9526-2246","authenticated-orcid":false,"given":"Noemie","family":"Stanleigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-473X","authenticated-orcid":false,"given":"Michal","family":"Irony-Tur Sinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-8162","authenticated-orcid":false,"given":"Yifat","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-3254","authenticated-orcid":false,"given":"Efrat","family":"Ozeri-Galai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5394-9218","authenticated-orcid":false,"given":"Myriam","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-3686","authenticated-orcid":false,"given":"Liron","family":"Birimberg-Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-3756","authenticated-orcid":false,"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6223-5185","authenticated-orcid":false,"given":"Michael","family":"Wilschanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-0379","authenticated-orcid":false,"given":"Batsheva","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.01.001_bib0001","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.jcf.2026.01.001_bib0002","unstructured":"CFTR1 cystic fibrosis mutation database. April 2011 n.d. http:\/\/www.genet.sickkids.on.ca\/Home.html (accessed June 17, 2025)."},{"key":"10.1016\/j.jcf.2026.01.001_bib0003","unstructured":"CFTR2 clinical and functional translation of CFTR. 25 Sept 2024 n.d. https:\/\/cftr2.org\/ (accessed June 17, 2025)."},{"key":"10.1016\/j.jcf.2026.01.001_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ppul.20200","article-title":"Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy","volume":"40","author":"Kerem","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.01.001_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(93)91885-P","article-title":"Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C to T mutation","volume":"342","author":"Augarten","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1164\/ajrccm.155.6.9196095","article-title":"A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations","volume":"155","author":"Kerem","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.01.001_bib0008","doi-asserted-by":"crossref","first-page":"00587","DOI":"10.1183\/23120541.00587-2024","article-title":"Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry","volume":"11","author":"Mei-Zahav","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2026.01.001_bib0009","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1006\/geno.1998.5517","article-title":"The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C\u2192T mutation","volume":"53","author":"Chiba-Falek","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.jcf.2026.01.001_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-9525(01)02619-1","article-title":"Splicing regulation as a potential genetic modifier","volume":"18","author":"Nissim-Rafinia","year":"2002","journal-title":"Trends Genet"},{"key":"10.1016\/j.jcf.2026.01.001_bib0011","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Highsmith","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.01.001_bib0012","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2026.01.001_bib0013","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.01.001_bib0014","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1513\/AnnalsATS.202006-659OC","article-title":"Ivacaftor in people with cystic fibrosis and a 3849+10kb C \u2192 T or D1152H residual function mutation","volume":"18","author":"Kerem","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.01.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.01.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)00370-9","article-title":"Treatment effects of elexacaftor\/tezacaftor\/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant","author":"Heching","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0017","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.embor.7400273","article-title":"Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation","volume":"5","author":"Nissim-Rafinia","year":"2004","journal-title":"EMBO Rep"},{"key":"10.1016\/j.jcf.2026.01.001_bib0018","doi-asserted-by":"crossref","first-page":"36193","DOI":"10.1074\/jbc.274.51.36193","article-title":"Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides","volume":"274","author":"Friedman","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2026.01.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa490","article-title":"Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells","author":"Michaels","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.01.001_bib0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0021","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcf.2024.10.004","article-title":"A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T","volume":"24","author":"Caraco","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0022","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.01.001_bib0023","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jcf.2017.04.009","article-title":"Biobanking: towards increased access of biomaterials in cystic fibrosis. Report on the pre-conference meeting to the 13th ECFS Basic Science Conference, Pisa, 30 March-2 April 2016","volume":"16","author":"Beekman","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0024","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2026.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2026.01.001_bib0026","first-page":"347","article-title":"Tissue-based map of the human proteome","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jcf.2026.01.001_bib0027","unstructured":"CFTR. Hum protein atlas n.d. https:\/\/www.proteinatlas.org\/ENSG00000001626-CFTR."},{"key":"10.1016\/j.jcf.2026.01.001_bib0028","article-title":"Antisense oligonucleotide splicing modulation as a novel cystic fibrosis therapeutic approach for the W1282X nonsense mutation","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon elexacaftor\/tezacaftor\/ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.01.001_bib0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jcf.2026.01.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94564","article-title":"Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutations","volume":"2","author":"Vogel","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2026.01.001_bib0033","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2026.01.001_bib0034","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.001_bib0035","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.01.001_bib0036","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrg2673","article-title":"RNA processing and its regulation: global insights into biological networks","volume":"11","author":"Licatalosi","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jcf.2026.01.001_bib0037","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13059-025-03727-y","article-title":"Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals","volume":"26","author":"Palou-M\u00e1rquez","year":"2025","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcf.2026.01.001_bib0038","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1261\/rna.079585.123","article-title":"Targeting splicing factors for cancer therapy","volume":"29","author":"Bashari","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.jcf.2026.01.001_bib0039","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14348\/molcells.2023.2172","article-title":"Antisense oligonucleotide therapeutics for cystic fibrosis: recent developments and perspectives","volume":"46","author":"Kim","year":"2023","journal-title":"Mol Cells"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:12:26Z","timestamp":1793607146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000019"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.01.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}